Verastem, Inc. (VSTM)

Price$4.19

Value ScoreC

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-71.79%

Price vs S&P 500 (4W)-30.83%

VGM Score40.24

Market Capitalization$380.49M

All Metrics

Book Value / Share (Quarterly)$0.93

P/TBV (Annual)14.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)128.24%

Cash Flow / Share (Quarterly)$-1.83

Price vs S&P 500 (YTD)-54.85%

Gross Margin (TTM)85.13%

Net Profit Margin (TTM)-391.16%

EPS (TTM)$-2.51

10-Day Avg Trading Volume2.12M

EPS Excl Extra (TTM)$-2.51

Revenue Growth (5Y)-18.97%

EPS (Annual)$-3.02

ROI (Annual)-145.64%

Gross Margin (Annual)82.86%

Net Profit Margin (5Y Avg)-1674.50%

Cash / Share (Quarterly)$2.07

ROA (Last FY)-85.00%

Revenue Growth TTM (YoY)209.14%

EBITD / Share (TTM)$-2.12

ROE (5Y Avg)-154.64%

Operating Margin (TTM)-344.56%

Cash Flow / Share (Annual)$-1.89

P/B Ratio4.65x

P/B Ratio (Quarterly)5.69x

Net Income / Employee (Annual)$-2,053,600

EV / Revenue (TTM)6.00x

Net Interest Coverage (TTM)-314.86x

ROA (TTM)-91.56%

EPS Incl Extra (Annual)$-3.02

Current Ratio (Annual)3.09x

Quick Ratio (Quarterly)2.88x

3-Month Avg Trading Volume2.01M

52-Week Price Return-44.27%

Revenue / Employee (TTM)$486,100

Tangible BV / Share (Quarterly)$0.75

P/S Ratio (Annual)12.31x

Asset Turnover (Annual)0.13x

52-Week High$11.25

Operating Margin (5Y Avg)-1512.87%

EPS Excl Extra (Annual)$-3.02

CapEx CAGR (5Y)217.14%

Tangible BV CAGR (5Y)-3.85%

26-Week Price Return-55.86%

Quick Ratio (Annual)2.96x

13-Week Price Return-24.30%

Total Debt / Equity (Annual)1.51x

Current Ratio (Quarterly)3.04x

Enterprise Value$297.61M

Revenue / Share Growth (5Y)-42.22%

Asset Turnover (TTM)0.23x

Book Value / Share Growth (5Y)-7.04%

Revenue / Employee (Annual)$303,100

Pretax Margin (Annual)-677.59%

Cash / Share (Annual)$2.64

3-Month Return Std Dev67.51%

Gross Margin (5Y Avg)87.71%

Net Income / Employee (TTM)$-1,901,600

ROE (Last FY)-366.23%

Net Interest Coverage (Annual)-147.60x

EPS Basic Excl Extra (Annual)$-3.02

Receivables Turnover (TTM)0.35x

Total Debt / Equity (Quarterly)1.01x

EPS Incl Extra (TTM)$-2.51

Receivables Turnover (Annual)0.00x

ROI (TTM)-66.90%

P/S Ratio (TTM)7.67x

Pretax Margin (5Y Avg)-1674.08%

Revenue / Share (Annual)$0.45

Tangible BV / Share (Annual)$0.52

Price vs S&P 500 (52W)-72.48%

Year-to-Date Return-43.91%

5-Day Price Return2.12%

EPS Normalized (Annual)$-3.02

ROA (5Y Avg)-83.02%

Net Profit Margin (Annual)-677.59%

Month-to-Date Return-20.70%

Cash Flow / Share (TTM)$-3.92

EBITD / Share (Annual)$-2.48

Operating Margin (Annual)-556.24%

LT Debt / Equity (Annual)1.42x

ROI (5Y Avg)-90.60%

LT Debt / Equity (Quarterly)0.94x

EPS Basic Excl Extra (TTM)$-2.51

P/TBV (Quarterly)7.09x

P/B Ratio (Annual)10.17x

Inventory Turnover (TTM)21.26x

Pretax Margin (TTM)-391.16%

Book Value / Share (Annual)$0.74

Price vs S&P 500 (13W)-34.05%

Beta0.34x

Revenue / Share (TTM)$0.50

ROE (TTM)-163.59%

52-Week Low$4.00

vGradeC

gGradeC

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.46est. -0.47

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.27

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
VSTMVerastem, Inc.	C	C	D	$4.19
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Verastem Inc is a late-stage development biopharmaceutical company developing novel anticancer agents targeting critical signaling pathways in cancer. The company's pipeline is focused on RAF/MEK and FAK inhibition to suppress cancer cell survival and tumor growth.